This podcast episode explores the transformative potential of Smart Chemotherapy, a targeted therapy approach that combines antibodies with chemotherapy to deliver treatment directly to cancer cells. By using antibodies to target cancer cells more precisely, Smart Chemotherapy can reduce damage to healthy tissues, leading to improved outcomes and reduced side effects compared to traditional chemotherapy. The episode highlights the evolution of ADC drugs since their inception in the late 1990s, the growing recognition of their potential among large biopharma companies, and the increasing investment in Smart Chemotherapy. The revolution is underway in breast and bladder cancer, but expectations are high that Smart Chemotherapy will replace traditional chemotherapy in other solid tumors as well. With ongoing advances and promising proof-of-concept data in areas such as colorectal cancer, Smart Chemotherapy is poised to make a significant impact on the treatment of cancer.